Mersana Therapeutics to Present an Analysis from the Expansion Cohort of the Phase 1 Trial of Upifitamab Rilsodotin at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer
March 15 2022 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that it will
present an analysis based on the June 10th, 2021 data cut from the
expansion cohort of the Company’s Phase 1 trial of upifitamab
rilsodotin (UpRi) at the upcoming Society of Gynecologic Oncology
Annual Meeting on Women’s Cancer being held from March 18-21, 2022
in Phoenix, Arizona.
UpRi is a Dolaflexin ADC targeting NaPi2b and is being studied
in UPLIFT, a single-arm registrational trial in patients with
platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase
1/2 umbrella trial evaluating UpRi in combinations starting with
carboplatin. The Company plans to initiate UP-NEXT, a Phase 3 trial
of UpRi monotherapy maintenance in platinum-sensitive recurrent
ovarian cancer with a design informed by FDA and CHMP feedback, in
the second quarter of 2022.
“The upcoming presentation at SGO will include analysis from the
nearly 100 patients with ovarian cancer treated in the expansion
cohort of our UpRi Phase 1 trial based on the June 10th, 2021 data
cut which supported the decision to select 36 mg/m2 as the
recommended Phase 2 dose for UPLIFT. The data highlight UpRi’s
robust clinical activity and differentiated safety profile which
further support the design of the ongoing UPLIFT registrational
trial in platinum-resistant ovarian cancer,” said Anna Protopapas,
President and Chief Executive Officer of Mersana Therapeutics.
Details of the presentation and posters are as follows:
Oral Plenary Session Title: Updated Results
from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi;
XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate
(ADC) in Ovarian CancerAbstract #:
76Date/Time: Saturday, March 19, 2022 at 11:46 am
MST Oral Presenter: Debra L. Richardson, MD
Poster Title: Optimizing the Dose of Upifitamab
Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody
Drug Conjugate (ADC): Updated Analysis of a Phase 1b Expansion
Study in Ovarian CancerAbstract #:
319Poster Lead Author: Bradley J. Monk, MD
Poster Title: UPGRADE: Phase 1 Combination
Trial of the NaPi2b-directed Dolaflexin Antibody Drug Conjugate
(ADC) Upifitamab Rilsodotin (UpRi; XMT-1536) in Patients With
Ovarian CancerAbstract #: 588Poster Lead
Author: Nehal Lakhani, MD, PhD
Poster Title: UPLIFT (ENGOT-ov67/GOG-3048): A
Pivotal Cohort of Upifitamab Rilsodotin (XMT-1536; UpRi), a
NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in
Platinum-Resistant Ovarian CancerAbstract #:
585Poster Lead Author: Debra L. Richardson, MD
Additional information can be found on the SGO website.
About Mersana TherapeuticsMersana Therapeutics
is a clinical-stage biopharmaceutical company using its
differentiated and proprietary ADC platforms to rapidly develop
novel ADCs with optimal efficacy, safety and tolerability to
meaningfully improve the lives of people fighting cancer. Mersana’s
lead product candidate, upifitamab rilsodotin (UpRi), is a
Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a
single-arm registrational trial in patients with platinum-resistant
ovarian cancer, as well as in UPGRADE, a Phase 1/2 umbrella trial
evaluating UpRi in combination with other ovarian cancer therapies.
XMT-1592, Mersana’s second ADC product candidate targeting
NaPi2b-expressing tumors, was created using Mersana’s customizable
and homogeneous Dolasynthen platform and is in the dose exploration
portion of a Phase 1 clinical trial. The Company’s early-stage
programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as
well as XMT-2056, a STING-agonist ADC developed using the Company’s
Immunosynthen platform and targeting a novel epitope of human
epidermal growth factor receptor 2 (HER2). In addition, multiple
partners are using Mersana’s platforms to advance their ADC
pipelines. Mersana Therapeutics was recently named among the 2021
Top Places to Work in Massachusetts by the Boston Globe. The
Company routinely posts information that may be useful to investors
on the “Investors and Media” section of our website at
www.mersana.com.
Forward-Looking Statements
This press release contains “forward-looking” statements and
information within the meaning of The Private Securities Litigation
Reform Act of 1995. These forward-looking statements are not
statements of historical facts and are based on management’s
beliefs and assumptions. Forward-looking statements in this press
release include statements concerning the Company’s business
strategy and the design, progression and timing of its clinical
trials. Forward-looking statements generally can be identified by
terms such as “aims,” “anticipates,” “believes,” “contemplates,”
“continues,” “could,” “designed to,” “estimates,” “expects,”
“goal,” “intends,” “may,” “on track,” “opportunity,” “plans,”
“poised for,” “possible,” “potential,” “predicts,” “projects,”
“promises to be,” “seeks,” “should,” “strategy,” “target,” “will,”
“would” or similar expressions and the negatives of those terms.
Actual results or events could differ materially from the plans,
intentions and expectations disclosed in these forward-looking
statements as a result of various factors, including, among other
things, that the results of the Company’s ongoing or future
clinical trials may be inconclusive with respect to the efficacy of
the Company’s product candidates, that the Company may not meet
clinical endpoints with statistical significance or there may be
safety concerns or adverse events associated with its product
candidates, that preclinical testing or early clinical results may
not be predictive of the results or success of ongoing or later
preclinical studies or clinical trials, whether preliminary or
interim data from a clinical trial will be predictive of the final
results of the trial, that the identification, development and
testing of the Company’s product candidates and new platforms will
take longer and/or cost more than planned, availability of funding
sufficient for the Company’s foreseeable and unforeseeable
operating expenses and capital expenditure requirements, and that
the Company’s clinical trials may not be initiated or completed on
schedule, if at all, as well as those listed in the Company’s
Annual Report on Form 10-K filed on February 28, 2022, with the
Securities and Exchange Commission (“SEC”), and subsequent SEC
filings that the Company may make in the future.
Contact:Investor & Media ContactJames
Salierno 617-498-0020jsalierno@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Sep 2023 to Sep 2024